<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01897727</url>
  </required_header>
  <id_info>
    <org_study_id>F080821012</org_study_id>
    <secondary_id>R01HL075614</secondary_id>
    <nct_id>NCT01897727</nct_id>
  </id_info>
  <brief_title>Etiology of Sleep Apnea-related Hyperaldosteronism - BP Treatment</brief_title>
  <official_title>Randomized Controlled Trial of Spironolactone Versus Standard of Care Blood Pressure Treatment on the Severity of Obstructive Sleep Apnea in Patients With Resistant Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypertension affects an estimated 60-70 million Americans, predisposing them to potentially
      life threatening cardiovascular complications. Resistant hypertension, defined as
      uncontrolled blood pressure on 3 or more different antihypertensive agents, is common,
      affecting 15-20% of the entire hypertensive population or an estimated 12-14 million
      Americans. Although associated with obesity, increasing age, black race, and chronic kidney
      disease, mechanisms of treatment resistance remain obscure. The investigators' laboratory
      identified primary aldosteronism (PA) as a common cause of treatment resistance with a
      prevalence of 20% among subjects with resistant hypertension. This is clinically important
      because recognition of PA can lead to effective treatment with use of aldosterone blockers.
      Obstructive sleep apnea (OSA) is strongly associated with and predicts development of
      hypertension as demonstrated in landmark cohort studies including the Sleep Heart Health
      Study and the Wisconsin Sleep Cohort Study.

      The investigators' laboratory has confirmed OSA to be extremely common in subjects with
      resistant hypertension, with a prevalence of approximately 85%. Recognizing that PA and OSA
      are exceptionally common in subjects with resistant hypertension, the investigators
      hypothesized that the 2 may be causally related. In testing this hypothesis, the
      investigators recently reported that plasma aldosterone levels are positively correlated with
      OSA severity in subjects with resistant hypertension but not in normotensive control
      subjects. This observation suggests that there is an important mechanistic interaction
      between untreated OSA and aldosterone excess in subjects with resistant hypertension. While
      the investigators' original hypothesis was that OSA stimulates aldosterone release, the
      investigators recognize that the opposite may also be true; that is, aldosterone excess in
      subjects with resistant hypertension worsens OSA. Distinguishing between these two
      possibilities has potentially far-reaching clinical implications. If the former hypothesis is
      true, effective treatment of OSA would be expected to suppress aldosterone release in
      subjects with resistant hypertension, thereby reversing the underlying cause of their
      treatment resistance. If the latter hypothesis is true, use of mineralocorticoid receptor
      antagonists would be expected to reduce OSA severity in subjects with resistant hypertension,
      thereby enhancing treatment of OSA. Either scenario would represent a new treatment approach
      for a highly prevalent and serious medical problem.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Severity of Obstructive Sleep Apnea</measure>
    <time_frame>baseline and 3 months</time_frame>
    <description>3 month change in apnea-hypopnea index assessed by diagnostic, full-night polysomnography. AHI values are typically categorized as 5-15/hr = mild; 15-30/hr = moderate; and &gt; 30/h = severe.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <condition>Resistant Hypertension</condition>
  <condition>Hyperaldosteronism</condition>
  <arm_group>
    <arm_group_label>Spironolactone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Spironolactone 25 mg administered following baseline measurements and uptitrated to 50 mg if BP &gt; 140/90 mm Hg throughout the 3 month study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care BP treatment</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Antihypertensive medication added and/or uptitrated to keep BP &lt; 140/90 mm Hg throughout the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone</intervention_name>
    <arm_group_label>Spironolactone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BP medication uptitration</intervention_name>
    <description>antihypertensive medication added or uptitrated following standard of care</description>
    <arm_group_label>Standard of care BP treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Resistant hypertension defined as office BP that is uncontrolled with 3 or more
             antihypertensive medications

          -  Moderate-severe OSA defined as AHI â‰¥15 events/hr

          -  Self-reported adherence &gt;80% with prescribed antihypertensive medications.

        Exclusion Criteria:

          -  Ongoing use of a potassium sparing diuretic

          -  History of congestive heart failure (ejection fraction of &lt;40%)

          -  Chronic kidney disease (creatinine clearance &lt;60 ml/min)

          -  History of cardiovascular disease (stroke, TIA, myocardial infarction, or
             revascularization procedure)

          -  Known or suspected history of secondary cause of hypertension other than primary
             aldosteronism

          -  Severe nocturnal hypoxemia (O2 desaturation nadir &lt;60%)

          -  White coat hypertension defined as office BP &gt;140/90 mm Hg and ambulatory daytime BP
             &lt;135/85 mm Hg

          -  Central sleep apnea (defined as 5% or more of the apneas as central apneas) and/or the
             presence of any Cheyne-Stokes breathing

          -  Subjects working shift work or having other known circadian rhythm disorders such that
             their sleep-wake schedule is altered

          -  Excessive daytime sleepiness as indicated by an Epworth score of &gt;10

          -  Pregnant Women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gaddam K, Pimenta E, Thomas SJ, Cofield SS, Oparil S, Harding SM, Calhoun DA. Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report. J Hum Hypertens. 2010 Aug;24(8):532-7. doi: 10.1038/jhh.2009.96. Epub 2009 Dec 17.</citation>
    <PMID>20016520</PMID>
  </reference>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2013</study_first_submitted>
  <study_first_submitted_qc>July 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2013</study_first_posted>
  <results_first_submitted>September 3, 2013</results_first_submitted>
  <results_first_submitted_qc>December 13, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 15, 2014</results_first_posted>
  <last_update_submitted>December 13, 2013</last_update_submitted>
  <last_update_submitted_qc>December 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Eric Judd</investigator_full_name>
    <investigator_title>Sub investigator</investigator_title>
  </responsible_party>
  <keyword>sleep apnea</keyword>
  <keyword>hypertension</keyword>
  <keyword>aldosterone</keyword>
  <keyword>hyperaldosteronism</keyword>
  <keyword>spironolactone</keyword>
  <keyword>blood pressure</keyword>
  <keyword>resistant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
    <mesh_term>Hyperaldosteronism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Consecutive adult patients with symptoms of OSA and resistant HTN between 2009 to 2012, were enrolled from the Hypertension Clinic at the University of Alabama at Birmingham.</recruitment_details>
      <pre_assignment_details>There was no wash out; ongoing use of a potassium sparing diuretic, including spironolactone, eplerenone, triamterene, or amiloride precluded study participation.
A total of 17 participants (out of the 41 who were enrolled) were randomized into the two groups. 24 participants met exclusion criteria before randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Spironolactone</title>
          <description>Spironolactone 25 mg administered following baseline measurements and uptitrated to 50 mg if BP &gt; 140/90 mm Hg throughout the 3 month study.</description>
        </group>
        <group group_id="P2">
          <title>Standard of Care BP Treatment</title>
          <description>Antihypertensive medication added and/or uptitrated to keep BP &lt; 140/90 mm Hg throughout the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Exclusion: central sleep apnea</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Spironolactone</title>
          <description>Spironolactone 25 mg administered following baseline measurements and uptitrated to 50 mg if BP &gt; 140/90 mm Hg throughout the 3 month study.</description>
        </group>
        <group group_id="B2">
          <title>Standard of Care BP Treatment</title>
          <description>Antihypertensive medication added and/or uptitrated to keep BP &lt; 140/90 mm Hg throughout the study.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" spread="8.3"/>
                    <measurement group_id="B2" value="56.8" spread="6.3"/>
                    <measurement group_id="B3" value="58.4" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Severity of Obstructive Sleep Apnea</title>
        <description>3 month change in apnea-hypopnea index assessed by diagnostic, full-night polysomnography. AHI values are typically categorized as 5-15/hr = mild; 15-30/hr = moderate; and &gt; 30/h = severe.</description>
        <time_frame>baseline and 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Spironolactone</title>
            <description>Spironolactone 25 mg administered following baseline measurements and uptitrated to 50 mg if BP &gt; 140/90 mm Hg throughout the 3 month study.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care BP Treatment</title>
            <description>Antihypertensive medication added and/or uptitrated to keep BP &lt; 140/90 mm Hg throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Obstructive Sleep Apnea</title>
          <description>3 month change in apnea-hypopnea index assessed by diagnostic, full-night polysomnography. AHI values are typically categorized as 5-15/hr = mild; 15-30/hr = moderate; and &gt; 30/h = severe.</description>
          <units>events/hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.3" spread="16.1"/>
                    <measurement group_id="O2" value="7.0" spread="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Spironolactone</title>
          <description>Spironolactone 25 mg administered following baseline measurements and uptitrated to 50 mg if BP &gt; 140/90 mm Hg throughout the 3 month study.</description>
        </group>
        <group group_id="E2">
          <title>Standard of Care BP Treatment</title>
          <description>Antihypertensive medication added and/or uptitrated to keep BP &lt; 140/90 mm Hg throughout the study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Unanticipated enrollment challenges led to small numbers of participants analyzed.
Open-label study design may have prevented a placebo effect.
An outlier in AHI was present in the control group.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Eric Judd</name_or_title>
      <organization>University of Alabama at Birmingham</organization>
      <phone>205 934-9281</phone>
      <email>ejudd@uab.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

